Human cytomegalovirus peptide-HLA complex (HCMV pHLA)

Human cytomegalovirus (HCMV) peptide-HLA complexes are the primary molecular structures recognized by the host immune system to control CMV infection. These complexes are formed when viral proteins, most notably the immediate-early 1 (IE-1) and phosphoprotein 65 (pp65), are proteolytically processed into short peptides and loaded onto Human Leukocyte Antigen (HLA) Class I or II molecules for surface presentation [UniProt: P06725, P06725]. This presentation allows CD8+ and CD4+ T cells to identify and eliminate infected cells, a process that is vital for maintaining viral latency in healthy individuals [PubMed: 31142651]. In clinical settings, particularly among transplant recipients and immunocompromised patients, these complexes are the primary targets for immunotherapies such as CMV-specific adoptive T-cell transfer and multi-antigen vaccines like Triplex [PubMed: 29165304]. These therapies aim to restore or enhance the T-cell repertoire capable of recognizing these specific viral epitopes to prevent or treat CMV-related diseases like pneumonia, retinitis, and hepatitis. However, therapeutic challenges remain, including the virus's ability to downregulate HLA expression to evade detection and the potential for engineered T cells to cross-react with similar self-peptides [PubMed: 25605961].

Other names

HCMV IE-1/pp65 HLA complexCMV peptide-MHC complexCMV epitopesHCMV UL gene product epitopesCytomegalovirus antigen-HLA complex

Recognition of the peptide-HLA complex by the T-cell receptor (TCR) on CD8+ or CD4+ T cells, triggering cytotoxic T-lymphocyte (CTL) activation, cytokine release, and targeted lysis of HCMV-infected cells [PubMed: 25605961].